Anti-pan T lymphocyte ricin A chain immunotoxin (H65-RTA) and methylprednisolone for acute GVHD prophylaxis following allogeneic BMT from HLA-identical sibling donors

R. Krance, H. E. Heslop, H. Mahmoud, R. Ribeiro, E. Douglass, C. Hurwitz, V. Santana, L. Kun, M. M. Horowitz, M. K. Brenner

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Six patients (five children ≤ 12 years old and one young adult) underwent allogeneic BMT (not T lymphocyte-depleted) from sex-matched HLA-identical siblings. GVHD prophylaxis consisted of methylprednisolone (30 mg/m2) and anti pan T lymphocyte ricin A chain immunotoxin (H65-RTA) (0.1 mg/kg) administered daily for 12 consecutive doses. H65 RTA was initiated at day + 5 (n = 4) or day + 2 (n = 2). All patients engrafted. Despite receiving the planned GVHD prophylaxis, all patients developed moderate to severe acute GVHD; five patients developed Grade III/IV GVHD. Four patients died 34 to 78 days post-transplant; GVHD was a contributory cause of death in each case. H65 RTA as used in this study was ineffective for the prophylaxis of acute GVHD.

Original languageEnglish (US)
Pages (from-to)33-36
Number of pages4
JournalBone Marrow Transplantation
Volume11
Issue number1
StatePublished - Jan 1 1993

Fingerprint

Ricin
Immunotoxins
Methylprednisolone
Siblings
Tissue Donors
T-Lymphocytes
Young Adult
Cause of Death
zolimomab aritox
Thomsen-Friedenreich antibodies
Transplants

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Anti-pan T lymphocyte ricin A chain immunotoxin (H65-RTA) and methylprednisolone for acute GVHD prophylaxis following allogeneic BMT from HLA-identical sibling donors. / Krance, R.; Heslop, H. E.; Mahmoud, H.; Ribeiro, R.; Douglass, E.; Hurwitz, C.; Santana, V.; Kun, L.; Horowitz, M. M.; Brenner, M. K.

In: Bone Marrow Transplantation, Vol. 11, No. 1, 01.01.1993, p. 33-36.

Research output: Contribution to journalArticle

Krance, R, Heslop, HE, Mahmoud, H, Ribeiro, R, Douglass, E, Hurwitz, C, Santana, V, Kun, L, Horowitz, MM & Brenner, MK 1993, 'Anti-pan T lymphocyte ricin A chain immunotoxin (H65-RTA) and methylprednisolone for acute GVHD prophylaxis following allogeneic BMT from HLA-identical sibling donors', Bone Marrow Transplantation, vol. 11, no. 1, pp. 33-36.
Krance, R. ; Heslop, H. E. ; Mahmoud, H. ; Ribeiro, R. ; Douglass, E. ; Hurwitz, C. ; Santana, V. ; Kun, L. ; Horowitz, M. M. ; Brenner, M. K. / Anti-pan T lymphocyte ricin A chain immunotoxin (H65-RTA) and methylprednisolone for acute GVHD prophylaxis following allogeneic BMT from HLA-identical sibling donors. In: Bone Marrow Transplantation. 1993 ; Vol. 11, No. 1. pp. 33-36.
@article{3e0e5dfa2b9e42ad86dd8ab4c03ae4ef,
title = "Anti-pan T lymphocyte ricin A chain immunotoxin (H65-RTA) and methylprednisolone for acute GVHD prophylaxis following allogeneic BMT from HLA-identical sibling donors",
abstract = "Six patients (five children ≤ 12 years old and one young adult) underwent allogeneic BMT (not T lymphocyte-depleted) from sex-matched HLA-identical siblings. GVHD prophylaxis consisted of methylprednisolone (30 mg/m2) and anti pan T lymphocyte ricin A chain immunotoxin (H65-RTA) (0.1 mg/kg) administered daily for 12 consecutive doses. H65 RTA was initiated at day + 5 (n = 4) or day + 2 (n = 2). All patients engrafted. Despite receiving the planned GVHD prophylaxis, all patients developed moderate to severe acute GVHD; five patients developed Grade III/IV GVHD. Four patients died 34 to 78 days post-transplant; GVHD was a contributory cause of death in each case. H65 RTA as used in this study was ineffective for the prophylaxis of acute GVHD.",
author = "R. Krance and Heslop, {H. E.} and H. Mahmoud and R. Ribeiro and E. Douglass and C. Hurwitz and V. Santana and L. Kun and Horowitz, {M. M.} and Brenner, {M. K.}",
year = "1993",
month = "1",
day = "1",
language = "English (US)",
volume = "11",
pages = "33--36",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Anti-pan T lymphocyte ricin A chain immunotoxin (H65-RTA) and methylprednisolone for acute GVHD prophylaxis following allogeneic BMT from HLA-identical sibling donors

AU - Krance, R.

AU - Heslop, H. E.

AU - Mahmoud, H.

AU - Ribeiro, R.

AU - Douglass, E.

AU - Hurwitz, C.

AU - Santana, V.

AU - Kun, L.

AU - Horowitz, M. M.

AU - Brenner, M. K.

PY - 1993/1/1

Y1 - 1993/1/1

N2 - Six patients (five children ≤ 12 years old and one young adult) underwent allogeneic BMT (not T lymphocyte-depleted) from sex-matched HLA-identical siblings. GVHD prophylaxis consisted of methylprednisolone (30 mg/m2) and anti pan T lymphocyte ricin A chain immunotoxin (H65-RTA) (0.1 mg/kg) administered daily for 12 consecutive doses. H65 RTA was initiated at day + 5 (n = 4) or day + 2 (n = 2). All patients engrafted. Despite receiving the planned GVHD prophylaxis, all patients developed moderate to severe acute GVHD; five patients developed Grade III/IV GVHD. Four patients died 34 to 78 days post-transplant; GVHD was a contributory cause of death in each case. H65 RTA as used in this study was ineffective for the prophylaxis of acute GVHD.

AB - Six patients (five children ≤ 12 years old and one young adult) underwent allogeneic BMT (not T lymphocyte-depleted) from sex-matched HLA-identical siblings. GVHD prophylaxis consisted of methylprednisolone (30 mg/m2) and anti pan T lymphocyte ricin A chain immunotoxin (H65-RTA) (0.1 mg/kg) administered daily for 12 consecutive doses. H65 RTA was initiated at day + 5 (n = 4) or day + 2 (n = 2). All patients engrafted. Despite receiving the planned GVHD prophylaxis, all patients developed moderate to severe acute GVHD; five patients developed Grade III/IV GVHD. Four patients died 34 to 78 days post-transplant; GVHD was a contributory cause of death in each case. H65 RTA as used in this study was ineffective for the prophylaxis of acute GVHD.

UR - http://www.scopus.com/inward/record.url?scp=0027462743&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027462743&partnerID=8YFLogxK

M3 - Article

C2 - 8431709

AN - SCOPUS:0027462743

VL - 11

SP - 33

EP - 36

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 1

ER -